Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …

Epigenetics refers to the regulation of gene expression mainly by changes in DNA
methylation and modifications of histone proteins without altering the actual DNA sequence …

The therapeutic landscape is rapidly changing, with eight new drugs approved by the Food
and Drug Administration within the last 2 years, including midostaurin and gilteritinib for …

Acute myeloid leukemia (AML) remains a challenge to both patients and clinicians. Despite
improvements in our understanding of the disease, treatment has changed minimally and …

Epigenetic modifying enzymes such as histone deacetylases (HDACs), p300, and PRMT1
are recruited by AML1/ETO, the pathogenic protein for t (8; 21) acute myeloid leukemia …

Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …

As “Michael acceptors” may induce promiscuous responses in mammalian cells by reacting
with various proteins, we modified the cinnamamide of our previous hydrazide-based HDAC …

Epigenetic changes have been identified in recent years as important factors in the
pathogenesis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) …

Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating
gene expression, and behave as oncogenes in several cancer types, spurring the …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …